{"entity":{"id":"nct07513376","kind":"trial","name":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I ","aka":["INTerpath-014"],"tldr":"A phase 3 trial of Intismeran autogene in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) is a phase 3 interventional study registered as NCT07513376 by Merck Sharp & Dohme LLC, with 876 participants planned, started 2026-05-04 and due to reach its primary completion in 2034-08-22. Interventions recorded: Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07513376","url":"https://clinicaltrials.gov/study/NCT07513376"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","resectable-nsclc"],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":["intismeran-autogene"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07513376","phase":"3","setting":"A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT07513376","source":"https://clinicaltrials.gov/study/NCT07513376","fetchedAt":"2026-10-07T16:55:47.566Z","studySha256":"68ca822f70343a278b8e0a5f4b6b2ea6b4aeb69a2d7eeb0e2f8f4696d85eb723","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-01","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":876,"enrolmentType":"ESTIMATED","siteCount":104,"recruitingSiteCount":104,"countries":["Australia","Brazil","Canada","Chile","France","Germany","Greece","Hungary","Israel","Italy","Japan","Netherlands","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2026-05-04","startedType":"actual","enrolled":876,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07513376/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"drug":[{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}